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A BS TR AC T
BACKGROUND
Autoimmune and autoinflammatory diseases involve interactions between genetic 
risk factors and environmental triggers. We searched for a gene on chromosome 
17p13 that contributes to a group of epidemiologically associated autoimmune and 
autoinflammatory diseases. The group includes various combinations of general-
ized vitiligo, autoimmune thyroid disease, latent autoimmune diabetes in adults, 
rheumatoid arthritis, psoriasis, pernicious anemia, systemic lupus erythematosus, 
and Addison’s disease.
METHODS
We tested 177 single-nucleotide polymorphisms (SNPs) spanning the 17p13 linkage 
peak for association with disease and identified a strong candidate gene. We then 
sequenced DNA in and around the gene to identify additional SNPs. We carried out 
a second round of tests of association using some of these additional SNPs, thus 
elucidating the association with disease in the gene and its extended promoter re-
gion in fine detail.
RESULTS
Association analyses resulted in our identifying as a candidate gene NALP1, which 
encodes NACHT leucine-rich-repeat protein 1, a regulator of the innate immune 
system. Fine-scale association mapping with the use of DNA from affected families 
and additional SNPs in and around NALP1 showed an association of specific vari-
ants with vitiligo alone, with an extended autoimmune and autoinflammatory dis-
ease phenotype, or with both. Conditional logistic-regression analysis of NALP1 
SNPs indicated that at least two variants contribute independently to the risk of 
disease.
CONCLUSIONS
DNA sequence variants in the NALP1 region are associated with the risk of several 
epidemiologically associated autoimmune and autoinflammatory diseases, impli-
cating the innate immune system in the pathogenesis of these disorders.
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A utoimmune and autoinflammato-ry diseases are a group of about 80 disor-ders that can involve almost any tissue, 
organ, or system.1 A major source of illness and 
death, these diseases together affect 15 to 25 
million people in the United States,2 particularly 
women,3,4 in whom they rank among the top 10 
causes of death.5 The risk of autoimmune and 
autoinflammatory diseases is thought to depend 
on interactions between environmental factors and 
specific variants of specific genes, some of which 
may confer a risk that an individual disease will 
develop, and others a risk that several different 
diseases will develop.6
Indeed, many patients eventually have more 
than one autoimmune or autoinflammatory dis-
ease. Various names have been applied to different 
combinations of so-called multiple autoimmune 
disease, such as Schmidt’s syndrome and auto-
immune polyglandular syndromes. A few very rare 
multiple autoimmune disease syndromes result 
from mutations in single genes7; however, most 
cases of multiple autoimmune disease do not fol-
low mendelian patterns of inheritance, but rather 
have complex inheritance patterns. Susceptibility 
genes in these cases probably fall into two catego-
ries: some may specifically predispose patients to 
one or more of the component diseases, whereas 
others may affect the susceptibility of patients to 
autoimmune and autoinflammatory disease in 
general. The latter type of gene may represent a 
target in the treatment or even prevention of sev-
eral different diseases.
We8,9 and others have observed that, among 
patients with generalized vitiligo, there is an in-
creased frequency of several other autoimmune 
and autoinflammatory diseases, particularly auto-
immune thyroid disease (Graves’ disease and 
autoimmune hypothyroidism), latent autoimmune 
diabetes in adults, rheumatoid arthritis, psoriasis, 
pernicious anemia, systemic lupus erythemato-
sus, and Addison’s disease. There is also an in-
creased frequency of these same disorders among 
first-degree relatives of patients with vitiligo, sug-
gesting that some families have a genetic predis-
position to this group of autoimmune and auto-
inflammatory diseases. By testing for genetic 
linkage between disease and polymorphic DNA 
markers spanning the whole genome in families 
with vitiligo and other autoimmune and autoin-
flammatory diseases, we have identified several 
chromosomal regions (or loci) that appear to con-
tribute to this epidemiologic association, includ-
ing one on chromosome 17p13.10 This genomic 
region also appears to contribute to systemic lupus 
erythematosus in members of families who in-
herit lupus together with either vitiligo11 or vari-
ous other autoimmune and autoinflammatory 
diseases.12 This finding suggests that chromo-
some 17p13 is involved in the susceptibility to 
multiple autoimmune disease. To identify the auto-
immunity susceptibility gene in the 17p13 region, 
we performed fine-scale genetic association and 
DNA sequence analyses in 114 families with viti-
ligo and associated autoimmune and autoinflam-
matory diseases. 
Me thods
SUBJECTS
We obtained DNA samples from 656 persons 
from 114 extended families with multiple auto-
immune disease associated with vitiligo from the 
United States and United Kingdom between 1996 
and 2005. All families were white (as self-reported 
on multiple-answer questionnaires; see the Sup-
plementary Appendix, available with the full text 
of this article at www.nejm.org) and were selected 
on the basis of having two or more family mem-
bers with generalized vitiligo (multiplex families) 
and at least one having one or more of the other 
autoimmune and autoinflammatory diseases epi-
demiologically associated with vitiligo (autoim-
mune thyroid disease, rheumatoid arthritis, latent 
autoimmune diabetes in adults, psoriasis, perni-
cious anemia, systemic lupus erythematosus, and 
Addison’s disease).8,9 We studied two series of fam-
ilies. The first series comprised the 51 extended 
families (333 persons) we previously studied to 
map a vitiligo–multiple autoimmune disease locus 
to 17p13,10 and the second series comprised 63 
similar, independent families (323 persons). Clin-
ical information on all families from the first se-
ries and on about half the families from the sec-
ond have been reported previously.9
Available affected and unaffected family mem-
bers completed a detailed questionnaire to pro-
vide the clinical history with regard to approxi-
mately 50 autoimmune and autoinflammatory 
diseases and immune-related diseases, including 
vitiligo, autoimmune thyroid disease (Graves’ dis-
ease and autoimmune hypothyroidism), rheuma-
toid arthritis, psoriasis, pernicious anemia, sys-
temic lupus erythematosus, Addison’s disease, and 
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diabetes (for which type, age of onset, and course 
of treatment were specified). All patients with viti-
ligo provided a skin-lesion map.
The study investigators reviewed all data from 
the questionnaires and the lesion maps and the 
study staff examined most family members, both 
affected and unaffected. Inclusion criteria for fam-
ily members with generalized vitiligo were the 
presence of depigmented patches of skin that were 
acquired; that had changed in extent and bound-
aries over time; that were nonfocal and bilateral; 
that typically initially involved the fingers, hands, 
feet, face, or crural areas; and that were not as-
sociated with concurrent underlying eczema or 
psoriasis or with exposure to depigmenting chem-
icals. Family members with diagnoses that were 
considered to be questionable on the basis of stan-
dard diagnostic criteria13 were excluded. Table 1 
provides a summary of autoimmune diseases in 
the 114 study families (see Table 1 in the Supple-
mentary Appendix for details of the clinical diag-
noses).
Our study was approved by the Colorado Mul-
tiple Institutional Review Board and the South 
Thames Regional Multicentre Research Ethics 
Committee. Written informed consent was ob-
tained from all participants.
GENOTYPING
DNA was prepared from peripheral-blood speci-
mens with the use of a genomic DNA purifica-
tion kit (Puregene, Gentra Systems) or from saliva 
specimens with the use of a DNA self-collection 
kit (Oragene, DNA Genotek). We initially used the 
Illumina genotyping service to genotype family 
members in the first series, assaying 177 known 
single-nucleotide polymorphisms (SNPs) selected 
from the Illumina SNP Knowledge Resource. Each 
SNP had a minor allele frequency exceeding 0.10 
(i.e., the less common variant of the SNP occurred 
on at least 10% of chromosomes) in whites; alto-
gether, these SNPs captured approximately 18% 
of the common genetic variation (r2≥0.5) across 
the genetic-linkage region of chromosome 17p (ap-
proximately 11.3 cM, or 6.19 Mb). We genotyped 
family members in the second series for the 23 
SNPs that were significantly associated with dis-
ease in the first series according to both the 
pedigree disequilibrium test14 and the family-based 
association test.15 We then genotyped two inser-
tion–deletion polymorphisms and 78 additional 
SNPs in all 114 families (both series combined). 
We identified most of these 78 SNPs by sequenc-
ing NALP1, the gene for NACHT leucine-rich-re-
peat protein 1, and its extended promoter region 
in 15 genetically informative family members. Ad-
ditional details of genotyping are provided in the 
Supplementary Appendix.
DNA SEQUENCING
Having narrowed the 17p13 autoimmunity locus 
to NALP1 and its extended promoter region, we 
sought to identify DNA sequence variants within 
this region that we could use for further tests of 
association and for identification of the causal 
SNP or SNPs. We therefore sequenced 82.9 kb of 
the NALP1 gene and its extended promoter region 
in each of four parents (two from each series) who 
were heterozygous for a haplotype (a set of SNP 
alleles that occur on a single chromosome) of three 
adjacent Illumina SNPs (rs3926687, rs2733359, and 
rs878329) that initially appeared to confer a high 
risk (haplotype 1) and who had transmitted this 
haplotype to at least one affected offspring. We 
sequenced the same region in 11 unrelated patients 
who were homozygous for haplotype 1 (8 from the 
first series and 3 from the second series). Most of 
these patients had vitiligo and at least one other 
autoimmune disease. The sequenced regions in-
cluded a contiguous segment of 69.1 kb that 
spanned the extended NALP1 promoter region and 
exons 1, 2, and 3, as well as 11 individual segments 
containing exons 4 through 18 with 90 to 500 bp 
of adjacent intronic sequences. We sequenced 
several small introns completely. The regions that 
we sequenced define the five known alterna-
tively spliced isoforms of NALP1 messenger RNA 
(mRNA); approximately 77% of the sequence was 
Table 1. Autoimmune and Autoinflammatory Disease Phenotypes  
in 114 Multiplex Families.*
Disease Phenotype No. of Cases
Vitiligo only 219
Vitiligo and autoimmune thyroid disease 70
Vitiligo, autoimmune thyroid disease, and other, nonthyroid 
autoimmune disease
20
Vitiligo and other autoimmune disease 60
Autoimmune thyroid disease only 86
Autoimmune thyroid disease and other autoimmune disease 23
Other autoimmune disease only 89
* A total of 567 family members reported at least one autoimmune and auto-
inflammatory disease; 175 reported more than one disease.
The New England Journal of Medicine 
Downloaded from nejm.org at ST GEORGES University on October 2, 2019. For personal use only. No other uses without permission. 
 Copyright © 2007 Massachusetts Medical Society. All rights reserved. 
Association of NALP1 with Multiple Autoimmune Disease
n engl j med 356;12 www.nejm.org march 22, 2007 1219
determined by analyzing both DNA strands. Nu-
cleotide positions were obtained from the human 
genome sequence for chromosome 17 from the 
National Center for Biotechnology Information 
(NCBI) (Build 36).
The predicted effect of the substitution of his-
tidine for leucine at position 155 (Leu155→His) 
on the secondary structure of the NALP1 protein 
was assessed with the use of the protein structure 
prediction server (PSIPRED).16 We investigated the 
potential effects of both alleles of all promoter-
region variants on transcription-factor binding 
motifs predicted with the use of the Transcription 
Element Search System (TESS)17 and rVista 2.0 
software.18
STATISTICAL ANALYSIS
Details on preliminary analyses, genetic-linkage 
analyses, and conditional logistic-regression anal-
ysis are given in the Supplementary Appendix. We 
tested for Hardy–Weinberg equilibrium in found-
ers (the earliest specified persons in lineages) and 
in persons not in the lineage, such as spouses, in 
all 114 families. Calculation of linkage disequi-
librium between markers of the NALP1 region was 
carried out with Haploview software,19 version 
3.32. We also calculated the association of each 
marker with vitiligo or with an expanded auto-
immune phenotype considering as affected per-
sons with any autoimmune or autoinflammatory 
disease associated with vitiligo using the family-
based association test,15 version 1.5.5, and the ped-
igree disequilibrium test,14 version 5.1, which pro-
vides a combined statistic accounting for allele 
transmission to both affected offspring and un-
affected offspring. Haplotype-based transmission-
disequilibrium statistics were calculated with the 
use of the family-based association test, version 
1.5.5. P values of less than 0.05 were considered 
to indicate statistical significance.
R esult s
GENETIC-LINKAGE ANALYSIS
We previously reported10 genetic linkage between 
a locus on chromosome 17p13 and multiple auto-
immune disease associated with vitiligo, a result 
obtained by genotyping microsatellite markers 
across the genome in 51 extended families (the 
first series). In other families with vitiligo only, 
there was no linkage to this chromosomal re-
gion.10 With the use of these same data but an 
improved error-checking algorithm,20 the maxi-
mum multipoint lod score was 4.59 (P = 2.14×10−6) 
— an improvement on the previously obtained 
lod score of 4.00.10 The multipoint maximum lod 
score occurred at approximately 4.3 cM on chro-
mosome 17p; the linkage region encompassing a 
1-lod reduction from the maximum (thus, the re-
gion that probably contains the causal gene) 
spanned 11.3 cM (Fig. 1A).
FAMILY-BASED ASSOCIATION STUDIES
There are approximately 80 known or predicted 
genes within the 11.3-cM region spanning the 
linkage peak on chromosome 17p. To determine 
which of these genes is most likely to contribute 
to multiple autoimmune disease associated with 
vitiligo, we genotyped the families in the first 
series for the 177 SNPs spanning the linkage 
peak. The frequencies of all SNPs in founders and 
spouses who had married into the family were 
consistent with Hardy–Weinberg equilibrium. Ge-
netic-linkage analysis incorporating both SNP and 
microsatellite data did not result in a significant 
narrowing of the linkage peak (results not shown). 
We then tested for an allelic association of these 
SNPs with vitiligo alone and with the entire group 
of autoimmune and autoinflammatory diseases as-
sociated with vitiligo, considering a family mem-
ber with any of these diseases as “affected.” We 
used both the pedigree disequilibrium test14 and 
the family-based association test,15 which yielded 
generally similar results (Table 2 in the Supplemen-
tary Appendix). Both tests showed that 23 SNPs 
were associated with the vitiligo phenotype, with 
the expanded autoimmune and autoinflammatory 
disease phenotype, or with both, including a clus-
ter of five adjacent SNPs — rs2301582, rs9889625, 
rs3926687, rs2733359, and rs878329 — spanning 
a 117-kb region (Fig. 1B).
To assess the reproducibility of these candi-
date association signals, we carried out an inde-
pendent analysis in which we genotyped the 23 
significant SNPs in a second series of 63 extended 
families with multiple autoimmune disease as-
sociated with vitiligo. The results of this analysis 
provided support for an association of three of 
the five adjacent SNPs — rs3926687, rs2733359, 
and rs878329 — with the vitiligo phenotype and 
with the expanded autoimmune and autoinflam-
matory disease phenotype, both in the second 
series and in all 114 families (Fig. 1B, and Table 
2 in the Supplementary Appendix).
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These three high-risk SNPs span a 61-kb seg-
ment that includes the proximal coding region 
and the extended promoter region of NALP1, which 
encodes a key regulator of the innate immune 
system (Fig. 1C). The genomic region around 
NALP1 is gene-sparse; SNPs located downstream 
of NALP1 were not associated with disease, and 
the closest upstream gene, KIAA0523, is more than 
486 kb toward the centromere from NALP1. The 
results of the family-based association test showed 
that a preliminary haplotype defined by these three 
SNPs (haplotype 1) had the most significant as-
sociation with both the vitiligo phenotype and 
the expanded autoimmune and autoinflamma-
tory disease phenotype in the first series (P = 0.01 
and P = 0.009, respectively), in the second series 
(P = 0.03 and P = 0.02, respectively), and in both 
series combined (P<0.001 for both comparisons; 
odds ratio for vitiligo, 1.85; 95% confidence in-
terval [CI], 1.25 to 2.71; odds ratio for autoimmune 
and autoinflammatory disease, 1.79; 95% CI, 1.25 
to 2.56). Of the 177 SNPs initially tested, 98 clus-
tered into 21 blocks of linkage disequilibrium. 
With regard to correction for multiple testing, the 
177 SNPs constituted approximately 100 indepen-
dent tests (21 blocks of linkage disequilibrium and 
the 79 remaining SNPs), with a corrected P value 
of 0.04 for vitiligo-associated autoimmune and 
autoinflammatory diseases.
SEQUENCE analysiS AND HIGH-DENSITY 
association analysiS
Sequence analysis of NALP1 and its extended pro-
moter region was performed in 11 persons with 
vitiligo who were homozygous for haplotype 1 and 
in 4 unaffected heterozygotes who had transmit-
ted haplotype 1 to at least one affected offspring. 
The analysis yielded a total of 261 sequence vari-
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Figure 1. Association of Autoimmune Disease  
with the Chromosome 17 Linkage Region and NALP1.
Panel A shows the nonparametric multipoint lod scores 
for markers across chromosome 17 for 51 multiplex 
families with vitiligo-associated multiple autoimmune 
and autoinflammatory disease. Panel B shows the dis-
tribution of 177 single-nucleotide polymorphisms 
(SNPs) genotyped across the 17p linkage region, from 
0.04 to 6.24 Mb, in the same 51 families. The 23 SNPs 
that were each significantly associated with disease in 
these 51 families (red bars and red circles) were then 
genotyped in a replicate series of 63 similar families 
(red circles indicate SNPs that were significantly associ-
ated with disease in these families) (see Table 2 in the 
Supplementary Appendix). Panel C shows the negative 
log10 of the P values from the pedigree disequilibrium 
test for the 85 variants (83 SNPs and 2 insertion–dele-
tion polymorphisms) genotyped across the NALP1 re-
gion of chromosome 17p in all 114 families. Green cir-
cles indicate the vitiligo phenotype, and orange circles 
indicate the extended autoimmune and autoinflamma-
tory disease phenotype. The 18 exons of the NALP1 
structural gene are indicated by the black bars (tran-
scriptional orientation shown from right to left, blue ar-
row). Panel D shows pairwise r2 values for linkage dis-
equilibrium (with darker boxes indicating stronger 
disequilibrium) among the 19 of the 85 NALP1 region 
markers shown in Panel C that were most consistently 
associated with disease and thus were used in condi-
tional logistic-regression analyses, graphed against the 
physical positions of the markers. Stars indicate mark-
ers for which potential independent effects could not 
be excluded through regression analysis.
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ants (Table 3 in the Supplementary Appendix), 54 
of which were newly discovered. We also identi-
fied a segment of 524 bp that was missing from 
the NCBI human chromosome 17 sequence, im-
mediately after nucleotide 5,466,866.
To define more precisely the NALP1 genomic 
region that confers susceptibility to autoimmune 
and autoinflammatory disease, we genotyped all 
114 families for 78 additional SNPs (identified 
by means of sequence analysis) (Fig. 1C) and two 
small insertion–deletion polymorphisms (Table 4 
in the Supplementary Appendix), selected on the 
basis of their physical positions, HapMap tag-SNP 
status, minor allele frequencies, and potential 
functional significance. The genotype frequen-
cies of all variants tested were consistent with 
Hardy–Weinberg equilibrium and were similar in 
the two series (data not shown). As shown in Fig-
ure 1C, many NALP1 region variants were associ-
ated with vitiligo (with P values ranging from 
0.048 to <0.001 and odds ratios ranging from 
1.39 to 2.08) or with associated autoimmune and 
autoinflammatory disease (with P values ranging 
from 0.04 to <0.001 and odds ratios ranging 
from 1.25 to 1.93), in a pattern broadly distrib-
uted across the proximal portion of the NALP1 
structural gene and its extended promoter region. 
In general, we observed a stronger association 
for the expanded autoimmune and autoinflam-
matory disease phenotype than for the smaller 
vitiligo subgroup (Table 4 in the Supplementary 
Appendix).
Apparent associations of disease with multiple 
markers in the NALP1 region may reflect multiple 
independent causal variants or may be a conse-
quence of linkage disequilibrium between multi-
ple markers and one true causal variant. The align-
ment of the genomic positions (Fig. 1C) and the 
linkage-disequilibrium pattern (Fig. 1D and Ta-
ble 2) of the 19 NALP1 region markers (17 SNPs 
and 2 insertion–deletion polymorphisms) for 
which an association with disease was replicated 
in the two series (by means of the pedigree dis-
equilibrium test and the family-based association 
test) suggested that at least two markers might 
be independently associated with disease. To dis-
tinguish markers that might reflect independent 
variants from those that merely reflect linkage 
disequilibrium, we carried out conditional logis-
tic-regression analyses21 of these 19 markers (Ta-
ble 2, and Table 5 in the Supplementary Appen-
dix). On the basis of this analysis, three markers 
(rs6502867, rs8182352, and rs4790797) had the 
largest individual effects both for the expanded 
autoimmune and autoinflammatory disease phe-
notype (odds ratios, 1.93, 1.81, and 1.82, respec-
tively; P<0.001 for all three markers) and for the 
vitiligo phenotype (odds ratios, 2.08, 2.01, and 
2.01, respectively; P< 0.001 for all three markers). 
The inclusion of rs6502867 significantly improved 
the fit of logistic-regression models that included 
any 1 of the 18 other markers; conversely, the fit 
of the model including rs6502867 was signifi-
cantly improved by the inclusion of any 1 of 15 of 
the 18 other markers (Table 5 in the Supplemen-
tary Appendix). These results provide further sup-
port for the existence of at least two independent 
variants in the NALP1 region associated with the 
risk of disease: one variant tagged by rs6502867 
and the other located further upstream, in the 
proximal coding region or in the transcriptional 
promoter.
The markers rs878329, rs7223628, rs8182352, 
and rs4790796 are in almost perfect linkage dis-
equilibrium with rs4790797 (Table 6 in the Sup-
plementary Appendix), indicating that these five 
SNPs, which span only 2107 bases, all represent 
the same signal. The colinearity among the five 
markers precludes logistic-regression analyses that 
include any two of them. Inclusion of rs4790797 
significantly improved the fit of models that in-
cluded any 1 of the 14 remaining markers, except 
for rs12150220 and rs2670660, whereas none of 
the 14 remaining markers, except for rs6502867, 
improved the fit of the model that included 
rs4790797. These results suggest that an associa-
tion of 11 of the 14 markers (rs961826, rs11078575, 
rs1877658, rs925597, rs925598, rs3926687, the 
12-bp deletion, rs2733359, rs35658367, rs2716914, 
and rs8182354) with disease may be secondary to 
linkage disequilibrium with the cluster of 5 SNPs 
represented by rs4790797. Overall, the marker 
most significantly associated with disease was 
rs4790797, but it could not be distinguished from 
rs12150220 and rs2670660 in the logistic-regres-
sion analysis (Table 5 in the Supplementary Ap-
pendix). The results for the vitiligo phenotype were 
similar to those for the expanded autoimmune 
and autoinflammatory disease phenotype, except 
that the association of rs12150220 with vitiligo 
also appeared to be secondary to linkage disequi-
librium with rs4790797.
Thus, we detected at least two independent sig-
nals associated with autoimmune and autoinflam-
matory diseases: one located within the NALP1 
structural gene, tagged by SNP rs6502867, and at 
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Table 2. Association of 19 NALP1 Variants with Vitiligo and Autoimmune and Autoinflammatory Disease  
in 114 Multiplex Families.*
Variant/Allele P Value Odds Ratio (95% CI)†
Pedigree 
Disequilibrium Test
Family-Based 
Association Test
Conditional Logistic-
Regression Analysis
Autoimmune and autoinflam-
matory disease
rs6502867/A <0.001 0.002 <0.001 1.93 (1.32–2.88)
rs961826/A 0.001 0.001 0.008 1.60 (1.14–2.24)
rs12150220/A 0.001 0.001 0.003 1.66 (1.19–2.31)
rs11078575/C 0.003 0.002 0.02 1.50 (1.08–2.08)
rs1877658/T 0.003 0.005 0.04 1.40 (1.01–1.93)
rs925597/A <0.001 <0.001 0.005 1.62 (1.16–2.27)
rs925598/A 0.001 0.002 0.004 1.63 (1.17–2.26)
rs3926687/T 0.002 0.003 0.006 1.59 (1.15–2.21)
12-bp deletion‡ 0.006 0.01 0.01 1.51 (1.10–2.09)
rs2670660/C <0.001 <0.001 0.003 1.68 (1.20–2.35)
rs2733359/G 0.002 0.001 0.005 1.64 (1.17–2.30)
rs35658367/ATGA 0.001 0.001 0.004 1.64 (1.17–2.31)
rs2716914/C 0.003 0.004 0.02 1.49 (1.08–2.07)
rs878329/G 0.005 0.001 0.003 1.63 (1.17–2.26)
rs7223628/G 0.002 <0.001 0.002 1.68 (1.21–2.35)
rs8182352/G 0.001 <0.001 <0.001 1.81 (1.28–2.56)
rs4790796/A 0.003 <0.001 0.001 1.73 (1.24–2.42)
rs4790797/T 0.002 <0.001 <0.001 1.82 (1.29–2.56)
rs8182354/A 0.004 0.001 0.002 1.69 (1.22–2.36)
Vitiligo
rs6502867/A 0.005 0.004 <0.001 2.08 (1.37–3.15)
rs961826/A 0.002 0.003 0.007 1.67 (1.15–2.41)
rs12150220/A 0.002 0.002 0.004 1.69 (1.18–2.41)
rs11078575/C 0.005 0.005 0.02 1.55 (1.09–2.19)
rs1877658/T 0.004 0.007 0.03 1.49 (1.04–2.10)
rs925597/A 0.002 0.003 0.005 1.69 (1.18–2.44)
rs925598/A 0.003 0.003 0.005 1.66 (1.16–2.36)
rs3926687/T 0.004 0.004 0.008 1.61 (1.14–2.29)
12-bp deletion‡ 0.001 0.009 0.007 1.66 (1.16–2.36)
rs2670660/C <0.001 0.001 0.002 1.80 (1.25–2.61)
rs2733359/G 0.001 0.004 0.004 1.75 (1.21–2.53)
rs35658367/ATGA <0.001 0.001 0.002 1.82 (1.24–2.67)
rs2716914/C 0.002 0.008 0.007 1.64 (1.15–2.35)
rs878329/G 0.002 0.003 0.002 1.75 (1.22–2.51)
rs7223628/G <0.001 0.002 0.001 1.82 (1.26–2.63)
rs8182352/G <0.001 <0.001 <0.001 2.01 (1.36–2.95)
rs4790796/A 0.001 0.002 0.001 1.83 (1.26–2.63)
rs4790797/T <0.001 0.001 <0.001 2.01 (1.39–2.91)
rs8182354/A 0.001 0.002 0.001 1.83 (1.27–2.64)
* The variants listed are those for which the association with disease was replicated by the pedigree disequilibrium test  
and the family-based association test in both series of families.
† Odds ratios were calculated from the coefficients of the regression equation.
‡ The 12-bp deletion includes nucleotides 5457169 through 5457180 (TATGACTATGTG).
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least one other, located within a 64.7-kb linkage 
disequilibrium block tagged by the nonsynony-
mous coding SNP rs12150220 (Leu155→His) and 
six promoter-region SNPs (rs2670660, rs878329, 
rs7223628, rs8182352, rs4790796, and rs4790797). 
The significance (P = 0.0001) of a model that in-
cludes two SNPs, rs6502867 and rs4790797, each 
of which represents one of the two independent 
association signals, was greater than that of ei-
ther individual SNP (P<0.001 for each), and the 
haplotype carrying both high-risk alleles con-
ferred the highest risk (odds ratio, 2.77; P<0.001) 
(Table 7 in the Supplementary Appendix).
We assessed the haplotype-specific effects of 
rs6502867 and rs4790797 (representing the clus-
ter of five SNPs with perfect linkage disequilib-
rium) by comparing logistic-regression models 
that included the additive effects of both loci, 
with and without accounting for linkage phase. 
We did not detect haplotype-specific effects, which 
indicates that it makes no difference whether the 
two variants in the NALP1 region are cis or trans 
to one another. We also used logistic-regression 
models to evaluate the mode of inheritance of 
risks individually associated with rs6502867 and 
rs4790797. These analyses favored an additive 
model with no dominant or recessive effects.
ANALYSIS OF NALP1 NONSYNONYMOUS  
CODING-REGION VARIANTS
A total of 15 SNPs in the NALP1 region predicted 
nonsynonymous amino acid substitutions in the 
NALP1 protein (Table 4 in the Supplementary Ap-
pendix). These 15 SNPs were included in the sec-
ond set of 78 SNPs tested for an association with 
disease in the 114 families (Fig. 1C), and only 
rs12150220 (Leu155→His) showed evidence of an 
association, both with vitiligo alone and with 
autoimmune and autoinflammatory diseases (P = 
0.002 and P = 0.001, respectively, by the pedigree 
disequilibrium test). Leu155→His is a nonconser-
vative substitution located between the N-termi-
nal pyrin and NACHT domains of the human 
NALP1 polypeptide. This region contains no known 
peptide motifs, but its amino acid sequence, in-
cluding residue Leu155, has been highly conserved 
through primate evolution, from bush baby to 
human (Fig. 2) — suggesting that the region is 
critical to protein function. Indeed, the predicted 
secondary structure of the region has been even 
more highly conserved than its sequence.
NALP1 PROMOTER-REGION VARIANTS
We observed a total of 205 variants in the ex-
tended promoter region, all of which were as-
sessed for predicted effects on transcription-fac-
tor binding motifs. Five of the six tightly linked 
SNPs in the promoter region that were associated 
with disease were found to affect high-probabil-
ity mammalian transcription-factor binding sites 
(Table 3). Furthermore, rs2670660 occurs within 
a segment that is remarkably conserved in the 
human, chimpanzee, macaque, bush baby, cow, 
mouse, and rat, suggesting that this variant is 
functionally significant. It alters predicted bind-
ing motifs for the transcription factors HMGA1 
[HMG-I(Y)] and MYB. MYB regulates transcrip-
tion during the differentiation, proliferation, and 
apoptosis of erythroid, myeloid, and lymphoid cell 
lineages. Whether any of these sequence variants 
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affects NALP1 transcription in humans requires 
further investigation.
Discussion
Our study shows that variants of NALP1 confer 
susceptibility to autoimmune and autoinflam-
matory diseases that are associated with vitiligo. 
Confirmation of this finding will require addi-
tional studies in other patient groups, including 
analysis of the extent to which NALP1 is specifi-
cally involved in the component autoimmune 
disorders. Furthermore, the SNPs that we have 
implicated may not be the causal variants; iden-
tification of such variants will require the dem-
onstration of specific effects on NALP1 transcrip-
tion, mRNA, or protein function. 
NALP1, also known as CARD7, DEFCAP, and NAC, 
is thought to mediate activation of the innate im-
mune system in response to so-called pathogen-
associated molecular patterns such as bacterial 
peptides.22-24 NALP1 is widely expressed at low 
levels but is expressed at a high level in immune 
cells, particularly T cells and Langerhans’ cells,25,26 
patterns that are consistent with the particular 
involvement of NALP1 in skin autoimmunity. 
NALP1 recruits the adapter protein ASC, caspase 
1, and caspase 5 to a complex termed the NALP1 
inflammasome,23,24,26 which activates the proin-
flammatory cytokine interleukin-1β. Serum in-
terleukin-1β levels are elevated in patients with 
generalized vitiligo,27 suggesting the involvement 
of this pathway in the pathogenesis of disease. 
NALP1 also appears to play a role in cellular apop-
tosis, its overexpression stimulating caspase-medi-
ated apoptosis in a variety of cell types.22,28,29
Mutations in at least two other NALP-related 
genes involved in the innate immune system are 
associated with autoinflammatory diseases. Vari-
ants in NOD2/CARD15 are associated with inflam-
matory bowel disease30,31 and the Blau syn-
drome.32 Mutations in NALP3/CIAS1, a homologue 
of NALP1 and a component of the NALP3 inflam-
masome,24,26 result in several autoinflammatory 
phenotypes, including the cold autoinflamma-
tory syndrome, the Muckle–Wells syndrome, and 
neonatal-onset multisystem inflammatory dis-
ease.33-35 Administration of an interleukin-1β in-
hibitor36,37 or a caspase-1 inhibitor38 ameliorates 
symptoms in patients with these disorders. If the 
association between NALP1 and autoimmune and 
autoinflammatory diseases is confirmed, and if 
NALP1 variants are found to result in the activa-
tion of interleukin-1β, then inhibitors of interleu-
kin-1β and caspase might be effective in the 
treatment or prevention of NALP1-associated auto-
immune and autoinflammatory diseases.
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Table 3. Predicted Transcription-Factor Binding Motifs Affected by NALP1 
Promoter-Region SNPs Associated with Disease.*
SNP
Nucleotide  
Position†
Transcription  
Factor L a L q
rs2670660 5,459,730
T HMGA1 [HMG-I(Y)] 22.00 0.917
C (high risk) MYB 12.00 1.000
rs878329 5,493,974
C PEBP2 18.00 0.900
G (high risk) —
rs7223628 5,495,192
A AP-1 18.00 0.900
NFAT-1 14.00 1.000
G (high risk) TCF2 (HNF-1B) 14.00 1.000
PU.1 14.00 1.000
rs8182352 5,495,711
A —
G (high risk) PR 12.00 1.000
rs4790797 5,496,043
C FOXF1 24.00 0.923
T (high risk) —
* The five SNPs are among the six promoter-region SNPs whose potential in-
dependent effects could not be ruled out by conditional logistic-regression 
analyses. La denotes the log-likelihood score. Lq, a measure of the goodness-
of-fit of the DNA sequence to the consensus binding motif, was calculated by 
dividing La by the maximum La possible for the site model; the best possible 
Lq was 1.000.
† The NALP1 exon 1 (the site of the start of translation) begins at nucleotide 
5,428,550.
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